SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (594)4/16/1998 7:53:00 AM
From: Gabe Fernandez  Respond to of 1491
 
how they assessed the severity of the head injury did they described their protocols



To: Cacaito who wrote (594)4/16/1998 9:30:00 AM
From: yosi s  Read Replies (1) | Respond to of 1491
 
Regarding the mortality
Expected mortality ranges from 18 to 24%,in control trials where the results are better than when studies are not done .
So the analysis you are doing is on the low side.
The question is if for some reason there is much lower than expected mortality in the placebo group. Otherwise this is IMPRESIVE.
( Can any one just dreammmmm Fast track and quick approval base on phase 2 studies. Did the FDA ever do that????????????.)


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News